Contineum Therapeutics

Update in progress

CTNM (NasdaqGS)

Contineum Therapeutics, Inc. is a clinical‑stage biopharmaceutical company developing small‑molecule therapies for neuroscience, inflammation, and immunology indications in the United States. Its lead asset, PIPE‑791, is a brain‑penetrant LPA1 receptor inhibitor for idiopathic pulmonary fibrosis and chronic pain. PIPE‑307 targets muscarinic M1 receptors for depression and relapse‑remitting multiple sclerosis. Formerly Pipeline Therapeutics, renamed in Nov 2023; incorporated 2009 and based in San Diego, California.